In: Olivier KJJ, Hurvitz SA, eds. Antibody-Drug Conjugates. Hoboken, New Jersey: John Wiley & Sons, Inc., 2016:1-32.Lambert JM. Typical antibody-drug conjugates. In: Olivier Jr KJ, Hurvitz SA, editors. Antibody-drug conjugates: fundamentals, drug development, and clinical outcomes to ...
antibody–drug conjugatetargeted deliverycancer therapycombination therapyLiu, XinyuDepartment of Biomedical Engineering, School of Medicine Tsinghua University Beijing PR ChinaGao, WeipingDepartment of Biomedical Engineering, School of Medicine Tsinghua University Beijing PR China...
Monica WhitmireAlan Breau
antibody‐drug conjugateslysosomesreceptor internalizationresistant cell populationsMack, MichelleOncology Research Unit World Wide Research and Development, Pfizer Inc. Pearl River NY USAKahler, JenniferOncology Research Unit World Wide Research and Development, Pfizer Inc. Pearl River NY USAShor, Boris...
Li X, Fang T, Boons G-J (2014) Preparation of well-defined antibody- drug conjugates through glycan remodeling and strain-promoted azide- alkyne cycloadditions. Angew Chem Int Ed 53:7179-7182Li, X.; Fang, T.; Boons, G.J. Preparation of well-defined antibody-drug conjugates through ...
presenting challenges in the management of the disease. Antibody–drug conjugates (ADCs) represent a promising therapeutic category for the treatment of breast cancer. Trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) are currently approved ADCs. These molecules have been pivotal, demo...
Antibody–drug conjugates (ADCs) have greatly improved the outcomes of advanced breast tumors. However, the treatment of breast tumors with existing ADCs is still hindered by many issues, such as tumor antigen heterogeneity and drug resistance. Therefore, ADCs against new targets would provide options...
It is true that nanobody–drug conjugates are endocytosed but they do not benefit from the EPR effect in the systemic circulation due to their small size. Thus, nanobody–drug conjugates for cancer therapy should be devised to take the EPR effect. 11A4-ABD-maleimide-auristatin F that can ...
Antibody–Drug Conjugates (ADCs), utilises this unique feature to kill cancerous cells. ADCs consist of an antibody linked with a cytotoxic payload, mainly targeting the antigen found on cancerous cells. This design can increase the specificity in delivering the cytotoxin to the drug target, thus...